Literature DB >> 16501608

Molecular mechanisms of hyperplasia induction by human papillomavirus E7.

T Ueno1, K Sasaki, S Yoshida, N Kajitani, A Satsuka, H Nakamura, H Sakai.   

Abstract

Infections of human papillomavirus (HPV) induce a variety of benign tumors, such as warts and condylomas. During the process of aberrant cell proliferation, genetic mutations are accumulated in the cells, from which malignant tumor cells arise. The viral oncoproteins E6 and E7 are known to help disrupt the cell cycle checkpoint machinery and accelerate chromosomal instability, events which are critical in malignant conversion. However, the mechanisms involved in the hyperplasia caused by HPV infection have remained unknown. We analysed the effects of regulatory genes of HPV18, a typical high-risk-type HPV, on the formation of the epithelial organ by using an organotypic culture system, and found that E7 had potent activity to induce hyperplasia, to which the disruption of the pRb pathway was well correlated. However, analysis with the E7 variants indicated that other pocket proteins are also involved in the activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501608     DOI: 10.1038/sj.onc.1209445

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  p63 maintains keratinocyte proliferative capacity through regulation of Skp2-p130 levels.

Authors:  Simon S McDade; Daksha Patel; Dennis J McCance
Journal:  J Cell Sci       Date:  2011-04-21       Impact factor: 5.285

2.  Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.

Authors:  Satoko Iwahori; Angie C Umaña; Halena R VanDeusen; Robert F Kalejta
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

3.  Deficiencies in Cellular Processes Modulated by the Retinoblastoma Protein Do Not Account for Reduced Human Cytomegalovirus Replication in Its Absence.

Authors:  Halena R VanDeusen; Robert F Kalejta
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

4.  Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein.

Authors:  Nicholas J Genovese; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

5.  The retinoblastoma tumor suppressor promotes efficient human cytomegalovirus lytic replication.

Authors:  Halena R VanDeusen; Robert F Kalejta
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

6.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

7.  Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins.

Authors:  Satoshi Yoshida; Naoko Kajitani; Ayano Satsuka; Hiroyasu Nakamura; Hiroyuki Sakai
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

8.  Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes.

Authors:  Nicholas J Genovese; N Sanjib Banerjee; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

9.  HPV18 E1^E4 is assembled into aggresome-like compartment and involved in sequestration of viral oncoproteins.

Authors:  Naoko Kajitani; Ayano Satsuka; Satoshi Yoshida; Hiroyuki Sakai
Journal:  Front Microbiol       Date:  2013-08-27       Impact factor: 5.640

10.  Molecular cloning and characterisation of a novel type of human papillomavirus 160 isolated from a flat wart of an immunocompetent patient.

Authors:  Tsuyoshi Mitsuishi; Ikuroh Ohsawa; Toshihiko Kato; Nagayasu Egawa; Tohru Kiyono
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.